Fig. 5From: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinomaPerformance of PIVKA-II in the diagnosis of AFP-negative HCC patients. ROC of PIVKA-II to distinguish HCC AFP-negative from healthy controls (HC) (a), and benign liver diseases (BLD) (b) respectivelyBack to article page